Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study

Systemic Lupus Erythematosus: nothing stale her infinite variety

(2018) Kenji Oku et al.   Modern Rheumatology

Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment

(2017) Yuka Shimizu et al.   Modern Rheumatology

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients

(2016) Bo Zheng et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

(2013) Rajesh Narwal et al.   CLINICAL PHARMACOKINETICS

Glucocorticoid use and abuse in SLE

(2012) G. Ruiz-Irastorza et al.   RHEUMATOLOGY

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Quality of life in cutaneous lupus erythematosus

(2011) Rachel Klein et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lupus: improving long-term prognosis

(2008) A Doria et al.   LUPUS